6.03
+0.5(+9.04%)
Currency In USD
Address
121 South Orange Avenue
Orlando, FL 32801
United States of America
Phone
407 377 6695
Website
Sector
Healthcare
Industry
Biotechnology
Employees
13
First IPO Date
October 01, 2021
| Name | Title | Pay | Year Born |
| Mr. Gareth Sheridan | Founder, Chief Executive Officer & Director | 155,000 | 1990 |
| Mr. Michael Myer | President of Pocono Pharmaceutical | 40,600 | 1984 |
| Mr. Gerald Goodman | Chief Financial Officer & Chief Accounting Officer | 115,000 | 1948 |
| Mr. Serguei Melnik | Founder, President, Company Secretary & Executive Chairman of the Board | 155,000 | 1974 |
| Dr. Alan Smith Ph.D. | Chief Operating Officer & President of 4P Therapeutics | 159,000 | 1966 |
| Dr. Jeffrey Patrick Pharm.D. | Chief Scientific Officer | 0 | 1970 |
| Mr. Tyler Overk | Head of Active Intelligence | 0 | 1984 |
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.